ArticleParasites & vectors2026
Efficacy of Credelio Quattro™ chewable tablets containing lotilaner, moxidectin, pyrantel, and praziquantel against Ctenocephalides felis and Rhipicephalus sanguineus infestations on dogs.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFleas and ticks can be found globally and are of both veterinary and human health concern due to their ability to transmit various vector-borne diseases. Heavy flea and tick infestations can result in significant blood loss, while flea infestations can result in intense pruritus. The use of safe and effective ectoparasiticides in veterinary medicine is a crucial part of protecting both pets and humans from infestations and transmission of vector-borne diseases.
methodsThe efficacy of a novel endectocide, Credelio Quattro, containing lotilaner, moxidectin, praziquantel, and pyrantel, was evaluated in four masked studies: one against Ctenocephalides felis and three against the dose-limiting tick Rhipicephalus sanguineus. Dogs were orally administered placebo, Credelio Quattro™, lotilaner only (Credelio™, Study 2), or pyrantel only (Study 2) in a fed state on Day 0. Experimental infestations with C. felis were conducted on Days -1, 6, 13, 20, 29, and 35 with 100 adult fleas. Fleas were removed and categorized as either live or dead 24 h post-treatment and 24 h post-infestation thereafter. Experimental infestations with R. sanguineus were conducted on Days -2, 5, 12, 19, and 30 with 50 adult ticks. Ticks were removed and categorized as attached or unattached and then live or dead 48 h post-treatment and 48 h post-infestation thereafter.
resultsCredelio Quattro demonstrated 100% (P < 0.0001) efficacy against C. felis, with no live fleas recovered at time points evaluated through 36 days post-treatment. Additionally, Credelio Quattro demonstrated 97.1-100% (P < 0.0001) efficacy through Day 30 against the established dose-limiting tick species, R. sanguineus. In Study 2, pyrantel demonstrated ≤ 46.6% (P ≥ 0.0601) efficacy while lotilaner provided ≥ 99.6% (P ≤ 0.0007) efficacy, confirming lotilaner as the acaricidal active ingredient in Credelio Quattro. Adverse events were reported in both treatment groups, including dermatitis, alopecia, lameness, and a chest wound. One dog in a Credelio Quattro treatment group experienced vomiting and bloody diarrhea that was considered possibly treatment-related.
conclusionsThese studies confirm the safety and effectiveness of a single dose of Credelio Quattro for the treatment and control of C. felis and R. sanguineus infestations on dogs for 1 month.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.